This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabatine, M. S. Articles by Antman, E. M. Search for Related Content PubMed Articles by Sabatine, M. S. Articles by Antman, E. M.

The thrombolysis in myocardial infarction risk score in unstable angina/non–ST-segment elevation myocardial infarction

^* TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA

Manuscript received May 7, 2002; revised manuscript received October 7, 2002, accepted December 18, 2002.

^* Reprint requests and correspondence: Dr. Marc S. Sabatine, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis Street, Boston, Massachusetts 02115, USA.
msabatine{at}partners.org

Risk stratification in unstable angina (UA)/non–ST-segment elevation myocardial infarction (NSTEMI) can provide an estimate of a patient’s prognosis and optimize clinical choices. The Thrombolysis In Myocardial Infarction (TIMI) risk score for UA/NSTEMI is an integrated approach that uses baseline variables that are part of the routine medical evaluation to identify patients at high risk for death and other major cardiac ischemic events. Using multivariable logistic regression, seven independent predictor variables were identified: age 65 years, 3 risk factors for coronary artery disease (CAD), known CAD (stenosis 50%), severe anginal symptoms (2 anginal events in preceding 24 h), use of aspirin in the last seven days, ST-segment deviation 0.05 mV, and elevated serum cardiac markers of necrosis. Each predictor carried similar prognostic weight; therefore, a risk score was constructed as the simple arithmetic sum of the number of predictors. The rate of death, MI, or urgent revascularization significantly increased as the TIMI risk score increased, ranging from <5% for patients with a risk score of 0 or 1 to >40% for patients with a risk score of 6 or 7. The risk score has been validated in several other trials of UA/NSTEMI. In addition, using the risk score to categorize patients also effectively defines a gradient for benefit with specific treatments such as low-molecular-weight heparins, glycoprotein IIb/IIIa inhibitors, and an early invasive strategy.

Abbreviations and Acronyms   ACC/AHA = American College of Cardiology/American Heart Association   CK-MB = creatine kinase-MB isoenzyme   cTn = cardiac troponin   ECG = electrocardiogram/electrocardiographic   GP = glycoprotein   LMWH = low-molecular-weight heparin   NSTEMI = non–ST-segment elevation myocardial infarction   RR = relative risk   UA = unstable angina   UFH = unfractionated heparin

This article has been cited by other articles:

				L. D. Hillis and R. A. Lange Optimal Management of Acute Coronary Syndromes N. Engl. J. Med., May 21, 2009; 360(21): 2237 - 2240. [Full Text] [PDF]

				D. Mudespacher, D. Radovanovic, E. Camenzind, M. Essig, O. Bertel, P. Erne, F. R. Eberli, and F. Gutzwiller Admission glycaemia and outcome in patients with acute coronary syndrome Diabetes and Vascular Disease Research, December 1, 2007; 4(4): 346 - 352. [Abstract] [PDF]

				P. Jeetley, L. Burden, and R. Senior Stress echocardiography is superior to exercise ECG in the risk stratification of patients presenting with acute chest pain with negative Troponin Eur J Echocardiogr, March 1, 2006; 7(2): 155 - 164. [Abstract] [Full Text] [PDF]

				T. J. Gluckman, M. Sachdev, S. P. Schulman, and R. S. Blumenthal A Simplified Approach to the Management of Non-ST-Segment Elevation Acute Coronary Syndromes JAMA, January 19, 2005; 293(3): 349 - 357. [Abstract] [Full Text] [PDF]

				B. S. Wiggins and S. Spinler Antiplatelet and Antithrombin Therapy for Early Management of Acute Coronary Syndromes Journal of Pharmacy Practice, October 1, 2004; 17(5): 347 - 369. [Abstract] [PDF]

				J. J. Popma, P. Berger, E. M. Ohman, R. A. Harrington, C. Grines, and J. I. Weitz Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 576S - 599S. [Abstract] [Full Text] [PDF]

				G. Montalescot, J.P. Collet, M.L. Tanguy, A. Ankri, L. Payot, R. Dumaine, R. Choussat, F. Beygui, V. Gallois, and D. Thomas Anti-Xa Activity Relates to Survival and Efficacy in Unselected Acute Coronary Syndrome Patients Treated With Enoxaparin Circulation, July 27, 2004; 110(4): 392 - 398. [Abstract] [Full Text] [PDF]